John E. Shively

City Of Hope National Medical Center — United States

Medicine · Health Sciences

87h-index27.1kcitations623works0.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Radiopharmaceutical Chemistry and Applications(231), Monoclonal and Polyclonal Antibodies Research(153), Peptidase Inhibition and Analysis(73), Neuropeptides and Animal Physiology(60), Glycosylation and Glycoproteins Research(59)

Publications623 total

First-in-human phase I trial combining radiopharmaceutical therapy (RPT) using a 90y-anti-CD25 monoclonal antibody (Mab) with total marrow and lymphoid irradiation (TMLI) in relapsed or refractory (R/R) acute leukemia
Blood·2025
Anti-CD38 targeted radiation is effective and enhances CAR-T cell recruitment and expansion in resistant extramedullary multiple myeloma
Blood·2025
Intestinal epithelial Ceacam1 deficiency prevents steroid-refractory acute gut graft-versus-host disease
JCI Insight·2025Open Access
Combination Image-Guided and Antibody-Targeted α-Therapy Before Targeted Immunotherapy for Treatment of Solid Tumors
Journal of Nuclear Medicine·2025Open Access
A pilot study of healing critical-sized calvarial defects by LL-37-generated monoosteophils
Frontiers in Bioengineering and Biotechnology·2025Open Access
Development and Potent Anti-Tumor Activity of a Fully Humanized Anti-TAG-72-IL-2 Fusion Protein for Therapy of Solid Tumors
Cancers·2025· 1 citedOpen Access
Olfactory receptors as tumor suppressors in cutaneous T-cell lymphoma via p38γ pathway modulation
Blood Neoplasia·2025Open Access
Supplementary Figure S.30 from Mathematical Modeling Unveils Optimization Strategies for Targeted Radionuclide Therapy of Blood Cancers
2025Open Access
Supplementary Figure S.20 from Mathematical Modeling Unveils Optimization Strategies for Targeted Radionuclide Therapy of Blood Cancers
2025Open Access
Supplementary Figure S.22 from Mathematical Modeling Unveils Optimization Strategies for Targeted Radionuclide Therapy of Blood Cancers
2025Open Access
Supplementary Figure S.26 from Mathematical Modeling Unveils Optimization Strategies for Targeted Radionuclide Therapy of Blood Cancers
2025Open Access
Supplementary Figure S.27 from Mathematical Modeling Unveils Optimization Strategies for Targeted Radionuclide Therapy of Blood Cancers
2025Open Access
Supplementary Figure S.21 from Mathematical Modeling Unveils Optimization Strategies for Targeted Radionuclide Therapy of Blood Cancers
2025Open Access
Supplementary Material from Mathematical Modeling Unveils Optimization Strategies for Targeted Radionuclide Therapy of Blood Cancers
2025Open Access
Supplementary Figure S.2 from Mathematical Modeling Unveils Optimization Strategies for Targeted Radionuclide Therapy of Blood Cancers
2025Open Access
Supplementary Figure S.1 from Mathematical Modeling Unveils Optimization Strategies for Targeted Radionuclide Therapy of Blood Cancers
2025Open Access
Supplementary Figure S.4 from Mathematical Modeling Unveils Optimization Strategies for Targeted Radionuclide Therapy of Blood Cancers
2025Open Access
Supplementary Figure S.7 from Mathematical Modeling Unveils Optimization Strategies for Targeted Radionuclide Therapy of Blood Cancers
2025Open Access
Supplementary Figure S.12 from Mathematical Modeling Unveils Optimization Strategies for Targeted Radionuclide Therapy of Blood Cancers
2025Open Access
Supplementary Figure S.11 from Mathematical Modeling Unveils Optimization Strategies for Targeted Radionuclide Therapy of Blood Cancers
2025Open Access
page 1 of 32Next →

Frequent Co-authors

Andrew Raubitschek(8), Mitsuru Haniu(6), Peter F. Hall(6), Lawrence E. Williams(6), Anna M. Wu(6), David H. Hawke(6), Joseph R. Reeve(5), Paul J. Yazaki(5), Sanjiv S. Gambhir(4), David Colcher(4), L Shively(3), Gobalakrishnan Sundaresan(3), Hema Pande(3), Jeffrey Y.C. Wong(3), Michael Neumaier(3), John H. Walsh(3), Stanley A. Hefta(3), L J Hefta(3), Jimmy Calaycay(2), Terry D. Lee(2)